UA80472C2 - 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolincarbonitriles for treating ischemic lesions - Google Patents

4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolincarbonitriles for treating ischemic lesions Download PDF

Info

Publication number: UA80472C2
Authority: UA; Ukraine
Prior art keywords: dichloro; methoxyphenyl; amino; methoxy; ethoxy
Prior art date: 2003-02-21

Application number

UAA200508924A

Other languages

English (en)

Ukrainian (uk)

Inventor

Margaret Maria Zaleska

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-21

Filing date

2004-02-19

Publication date

2007-09-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA80472(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-02-19 Application filed by Wyeth Corp filed Critical Wyeth Corp

2007-09-25 Publication of UA80472C2 publication Critical patent/UA80472C2/uk

Links

125000002924 primary amino group Chemical group [H]N([H])* 0.000 title claims description 64
-1 2,4-dichloro-5-methoxyphenyl Chemical group 0.000 title claims description 6
230000007654 ischemic lesion Effects 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 92
230000008728 vascular permeability Effects 0.000 claims abstract description 18
150000003839 salts Chemical class 0.000 claims abstract description 13
230000002401 inhibitory effect Effects 0.000 claims abstract description 6
125000000217 alkyl group Chemical group 0.000 claims abstract description 4
239000000203 mixture Substances 0.000 claims description 56
238000000034 method Methods 0.000 claims description 31
QZZYYBQGTSGDPP-UHFFFAOYSA-N quinoline-3-carbonitrile Chemical compound C1=CC=CC2=CC(C#N)=CN=C21 QZZYYBQGTSGDPP-UHFFFAOYSA-N 0.000 claims description 20
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 19
230000000302 ischemic effect Effects 0.000 claims description 19
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 18
208000006011 Stroke Diseases 0.000 claims description 16
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 claims description 12
206010061216 Infarction Diseases 0.000 claims description 10
230000007574 infarction Effects 0.000 claims description 10
208000024891 symptom Diseases 0.000 claims description 9
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
230000003993 interaction Effects 0.000 claims description 7
230000000324 neuroprotective effect Effects 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
206010021143 Hypoxia Diseases 0.000 claims description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
230000005764 inhibitory process Effects 0.000 claims description 5
230000001052 transient effect Effects 0.000 claims description 5
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 4
230000002490 cerebral effect Effects 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
238000007363 ring formation reaction Methods 0.000 claims description 4
230000001154 acute effect Effects 0.000 claims description 3
230000007954 hypoxia Effects 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
206010002660 Anoxia Diseases 0.000 claims description 2
241000976983 Anoxia Species 0.000 claims description 2
206010019196 Head injury Diseases 0.000 claims description 2
208000010496 Heart Arrest Diseases 0.000 claims description 2
206010028923 Neonatal asphyxia Diseases 0.000 claims description 2
208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims description 2
208000012902 Nervous system disease Diseases 0.000 claims description 2
208000025966 Neurological disease Diseases 0.000 claims description 2
230000007953 anoxia Effects 0.000 claims description 2
208000033300 perinatal asphyxia Diseases 0.000 claims description 2
VLCMRTMCMQJSKM-UHFFFAOYSA-N phenyl-[4-phenyl-8-(trifluoromethyl)quinolin-3-yl]methanone Chemical compound C=1C=CC=CC=1C(=O)C1=CN=C2C(C(F)(F)F)=CC=CC2=C1C1=CC=CC=C1 VLCMRTMCMQJSKM-UHFFFAOYSA-N 0.000 claims description 2
230000009467 reduction Effects 0.000 claims description 2
208000020431 spinal cord injury Diseases 0.000 claims description 2
208000005809 status epilepticus Diseases 0.000 claims description 2
239000003513 alkali Substances 0.000 claims 3
210000004204 blood vessel Anatomy 0.000 claims 2
238000001514 detection method Methods 0.000 claims 2
206010018985 Haemorrhage intracranial Diseases 0.000 claims 1
LELOWRISYMNNSU-UHFFFAOYSA-N Hydrocyanic acid Natural products N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims 1
208000008574 Intracranial Hemorrhages Diseases 0.000 claims 1
229910052736 halogen Inorganic materials 0.000 claims 1
150000002367 halogens Chemical class 0.000 claims 1
239000006207 intravenous dosage form Substances 0.000 claims 1
229940126601 medicinal product Drugs 0.000 claims 1
208000010125 myocardial infarction Diseases 0.000 claims 1
230000004776 neurological deficiency Effects 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
208000014674 injury Diseases 0.000 abstract description 9
230000006378 damage Effects 0.000 abstract description 7
208000027418 Wounds and injury Diseases 0.000 abstract description 6
201000010099 disease Diseases 0.000 abstract description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
230000008733 trauma Effects 0.000 abstract description 3
125000004432 carbon atom Chemical group C* 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 60
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 60
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 54
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
239000007787 solid Substances 0.000 description 34
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 32
238000004458 analytical method Methods 0.000 description 22
239000011541 reaction mixture Substances 0.000 description 20
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 18
239000000243 solution Substances 0.000 description 18
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
238000001914 filtration Methods 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 14
ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 14
239000012312 sodium hydride Substances 0.000 description 14
229910000104 sodium hydride Inorganic materials 0.000 description 14
238000011282 treatment Methods 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
208000028867 ischemia Diseases 0.000 description 13
239000002904 solvent Substances 0.000 description 13
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
239000012634 fragment Substances 0.000 description 12
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 12
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 11
239000000126 substance Substances 0.000 description 11
230000004927 fusion Effects 0.000 description 10
238000001990 intravenous administration Methods 0.000 description 10
239000007788 liquid Substances 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
238000010828 elution Methods 0.000 description 9
238000003818 flash chromatography Methods 0.000 description 9
108090000623 proteins and genes Proteins 0.000 description 9
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 8
XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
239000012044 organic layer Substances 0.000 description 7
238000001665 trituration Methods 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000004305 biphenyl Substances 0.000 description 6
235000010290 biphenyl Nutrition 0.000 description 6
210000003657 middle cerebral artery Anatomy 0.000 description 6
239000002245 particle Substances 0.000 description 6
AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 6
230000010410 reperfusion Effects 0.000 description 6
235000017557 sodium bicarbonate Nutrition 0.000 description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
241000700159 Rattus Species 0.000 description 5
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
208000037906 ischaemic injury Diseases 0.000 description 5
230000007971 neurological deficit Effects 0.000 description 5
238000012746 preparative thin layer chromatography Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
229910052938 sodium sulfate Inorganic materials 0.000 description 5
235000011152 sodium sulphate Nutrition 0.000 description 5
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
108010001336 Horseradish Peroxidase Proteins 0.000 description 4
208000032382 Ischaemic stroke Diseases 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
108091000080 Phosphotransferase Proteins 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
239000000908 ammonium hydroxide Substances 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
239000000969 carrier Substances 0.000 description 4
230000003197 catalytic effect Effects 0.000 description 4
230000007213 cerebrovascular event Effects 0.000 description 4
230000006735 deficit Effects 0.000 description 4
239000005457 ice water Substances 0.000 description 4
230000001771 impaired effect Effects 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
102000020233 phosphotransferase Human genes 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
239000000651 prodrug Substances 0.000 description 4
229940002612 prodrug Drugs 0.000 description 4
238000000746 purification Methods 0.000 description 4
235000009518 sodium iodide Nutrition 0.000 description 4
RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
230000004580 weight loss Effects 0.000 description 4
AJROJTARXSATEB-UHFFFAOYSA-N 2,4-dichloro-5-methoxyaniline Chemical compound COC1=CC(N)=C(Cl)C=C1Cl AJROJTARXSATEB-UHFFFAOYSA-N 0.000 description 3
DXOHZOPKNFZZAD-UHFFFAOYSA-N 2-ethylpiperazine Chemical compound CCC1CNCCN1 DXOHZOPKNFZZAD-UHFFFAOYSA-N 0.000 description 3
JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 3
BOQICIDBVOCNQA-UHFFFAOYSA-N 7-fluoro-6-methoxy-4-oxo-1h-quinoline-3-carbonitrile Chemical compound N1C=C(C#N)C(=O)C2=C1C=C(F)C(OC)=C2 BOQICIDBVOCNQA-UHFFFAOYSA-N 0.000 description 3
CKIFZMDHCWPBKW-UHFFFAOYSA-N 7-fluoro-6-methoxy-4-oxo-1h-quinoline-3-carboxylic acid Chemical compound OC(=O)C1=CN=C2C=C(F)C(OC)=CC2=C1O CKIFZMDHCWPBKW-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 3
206010015866 Extravasation Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
150000001298 alcohols Chemical class 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
210000005013 brain tissue Anatomy 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000006184 cosolvent Substances 0.000 description 3
MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
229960003699 evans blue Drugs 0.000 description 3
230000036251 extravasation Effects 0.000 description 3
210000002950 fibroblast Anatomy 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000001802 infusion Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000543 intermediate Substances 0.000 description 3
238000007912 intraperitoneal administration Methods 0.000 description 3
230000000926 neurological effect Effects 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
239000000047 product Substances 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
229920006395 saturated elastomer Polymers 0.000 description 3
230000001953 sensory effect Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
KJZLJGZZDNGGCA-UHFFFAOYSA-N (1-methylpiperidin-4-yl)methanol Chemical compound CN1CCC(CO)CC1 KJZLJGZZDNGGCA-UHFFFAOYSA-N 0.000 description 2
PGPXRIFFCBCWEO-UHFFFAOYSA-N 2-(1-methylpiperidin-4-yl)ethanol Chemical compound CN1CCC(CCO)CC1 PGPXRIFFCBCWEO-UHFFFAOYSA-N 0.000 description 2
FNJWLOHHZVGUIX-UHFFFAOYSA-N 2-propylpiperazine Chemical compound CCCC1CNCCN1 FNJWLOHHZVGUIX-UHFFFAOYSA-N 0.000 description 2
LJWAPDSCYTZUJU-UHFFFAOYSA-N 3-fluoro-4-methoxyaniline Chemical compound COC1=CC=C(N)C=C1F LJWAPDSCYTZUJU-UHFFFAOYSA-N 0.000 description 2
XLEYXHRMSUPJST-UHFFFAOYSA-N 3-fluoro-4-phenylmethoxyaniline Chemical compound FC1=CC(N)=CC=C1OCC1=CC=CC=C1 XLEYXHRMSUPJST-UHFFFAOYSA-N 0.000 description 2
HQWUPLKDABZELG-UHFFFAOYSA-N 4-chloro-7-fluoro-6-hydroxyquinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(F)C(O)=CC2=C1Cl HQWUPLKDABZELG-UHFFFAOYSA-N 0.000 description 2
NJBZOGXZFBSRIS-UHFFFAOYSA-N 7-fluoro-6-methoxy-4-oxo-1h-quinoline-3-carboxamide Chemical compound N1C=C(C(N)=O)C(=O)C2=C1C=C(F)C(OC)=C2 NJBZOGXZFBSRIS-UHFFFAOYSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
206010008111 Cerebral haemorrhage Diseases 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
208000005189 Embolism Diseases 0.000 description 2
229910052693 Europium Inorganic materials 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
150000001448 anilines Chemical class 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000030833 cell death Effects 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
210000003169 central nervous system Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
230000006835 compression Effects 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
KTMGNAIGXYODKQ-VOTSOKGWSA-N ethyl (e)-2-cyano-3-ethoxyprop-2-enoate Chemical compound CCO\C=C(/C#N)C(=O)OCC KTMGNAIGXYODKQ-VOTSOKGWSA-N 0.000 description 2
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
208000020658 intracerebral hemorrhage Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
210000000337 motor cortex Anatomy 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
230000007658 neurological function Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
238000011552 rat model Methods 0.000 description 2
238000011084 recovery Methods 0.000 description 2
239000012266 salt solution Substances 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 2
230000002792 vascular Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
KPYXMALABCDPGN-HYOZMBHHSA-N (4s)-5-[[(2s)-6-amino-1-[[(2s,3s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[2-[[2-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-2-oxoethyl]amino]-2-oxoethyl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]a Chemical class NC(=O)C[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN)CC1=CC=C(O)C=C1 KPYXMALABCDPGN-HYOZMBHHSA-N 0.000 description 1
QHTUMQYGZQYEOZ-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)ethanol Chemical compound CN1CCN(CCO)CC1 QHTUMQYGZQYEOZ-UHFFFAOYSA-N 0.000 description 1
MLIREBYILWEBDM-UHFFFAOYSA-M 2-cyanoacetate Chemical compound [O-]C(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-M 0.000 description 1
ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 description 1
229940093475 2-ethoxyethanol Drugs 0.000 description 1
JKRSQNBRNIYETC-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-ol Chemical compound CN1CCN(CCCO)CC1 JKRSQNBRNIYETC-UHFFFAOYSA-N 0.000 description 1
PNVRUIFACIJUKH-UHFFFAOYSA-N 4-chloro-7-fluoro-6-methoxyquinoline-3-carbonitrile Chemical compound N#CC1=CN=C2C=C(F)C(OC)=CC2=C1Cl PNVRUIFACIJUKH-UHFFFAOYSA-N 0.000 description 1
QNWHOCFQMBGSLT-UHFFFAOYSA-N 4-chloro-7-fluoro-6-phenylmethoxyquinoline-3-carbonitrile Chemical compound FC1=CC2=NC=C(C#N)C(Cl)=C2C=C1OCC1=CC=CC=C1 QNWHOCFQMBGSLT-UHFFFAOYSA-N 0.000 description 1
CRDISMZBOJPSJG-UHFFFAOYSA-N 7-fluoroquinoline-3-carbonitrile Chemical compound C1=C(C#N)C=NC2=CC(F)=CC=C21 CRDISMZBOJPSJG-UHFFFAOYSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
241000786798 Atya Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
201000006474 Brain Ischemia Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
101100411591 Dictyostelium discoideum rab8B gene Proteins 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
208000006893 Fetal Hypoxia Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000013016 Hypoglycemia Diseases 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
108700026244 Open Reading Frames Proteins 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
241000022563 Rema Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
241001648319 Toronia toru Species 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
238000003556 assay Methods 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
125000006267 biphenyl group Chemical group 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000012267 brine Substances 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
230000002612 cardiopulmonary effect Effects 0.000 description 1
210000004004 carotid artery internal Anatomy 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
208000026106 cerebrovascular disease Diseases 0.000 description 1
239000012320 chlorinating reagent Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000010367 cloning Methods 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
238000010276 construction Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
LTMHNWPUDSTBKD-UHFFFAOYSA-N diethyl 2-(ethoxymethylidene)propanedioate Chemical compound CCOC=C(C(=O)OCC)C(=O)OCC LTMHNWPUDSTBKD-UHFFFAOYSA-N 0.000 description 1
FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
206010014599 encephalitis Diseases 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
FUJNUQDCBRIKRF-UHFFFAOYSA-N ethyl 7-fluoro-6-methoxy-4-oxo-1h-quinoline-3-carboxylate Chemical compound C1=C(F)C(OC)=CC2=C(O)C(C(=O)OCC)=CN=C21 FUJNUQDCBRIKRF-UHFFFAOYSA-N 0.000 description 1
TVPIQWMPBCUNIW-UHFFFAOYSA-N ethyl N-ethoxycarbonyliminocarbamate oxolane Chemical compound C1CCOC1.CCOC(=O)N=NC(=O)OCC TVPIQWMPBCUNIW-UHFFFAOYSA-N 0.000 description 1
FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
239000003517 fume Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
239000008187 granular material Substances 0.000 description 1
238000004896 high resolution mass spectrometry Methods 0.000 description 1
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
229910000041 hydrogen chloride Inorganic materials 0.000 description 1
230000002218 hypoglycaemic effect Effects 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000001146 hypoxic effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000013067 intermediate product Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
208000023569 ischemic bowel disease Diseases 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
230000015654 memory Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000007659 motor function Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000001338 necrotic effect Effects 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
238000011859 neuroprotective therapy Methods 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
230000020477 pH reduction Effects 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000001144 postural effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
150000003140 primary amides Chemical class 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
238000011002 quantification Methods 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
230000011514 reflex Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000019705 regulation of vascular permeability Effects 0.000 description 1
210000005227 renal system Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
239000013049 sediment Substances 0.000 description 1
239000000344 soap Substances 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000002537 thrombolytic effect Effects 0.000 description 1
229960000187 tissue plasminogen activator Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000009529 traumatic brain injury Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000008096 xylene Substances 0.000 description 1
150000003738 xylenes Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

UAA200508924A 2003-02-21 2004-02-19 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolincarbonitriles for treating ischemic lesions UA80472C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US44931603P	2003-02-21	2003-02-21
PCT/US2004/004904 WO2004075898A1 (en)	2003-02-21	2004-02-19	4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury

Publications (1)

Publication Number	Publication Date
UA80472C2 true UA80472C2 (en)	2007-09-25

Family

ID=32927510

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200508924A UA80472C2 (en)	2003-02-21	2004-02-19	4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolincarbonitriles for treating ischemic lesions

Country Status (19)

Country	Link
US (1)	US20040229880A1 (es)
EP (1)	EP1594502A1 (es)
JP (1)	JP2006522023A (es)
KR (1)	KR20050102133A (es)
CN (1)	CN1750824A (es)
AR (1)	AR043253A1 (es)
AU (1)	AU2004216235A1 (es)
BR (1)	BRPI0407441A (es)
CA (1)	CA2516418A1 (es)
CO (1)	CO5640114A2 (es)
CR (1)	CR7931A (es)
EC (1)	ECSP055972A (es)
MX (1)	MXPA05008706A (es)
NO (1)	NO20054070L (es)
RU (1)	RU2005129333A (es)
TW (1)	TW200423938A (es)
UA (1)	UA80472C2 (es)
WO (1)	WO2004075898A1 (es)
ZA (1)	ZA200506621B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0416289A (pt)	2003-11-06	2007-01-23	Wyeth Corp	4-anilino-3-quinolinacarbonitrilas para o tratamento de leucemia mielógeno crÈnica (cml)
JP2008517924A (ja) *	2004-10-22	2008-05-29	ワイス	虚血傷害を処置するための４−［（２，４−ジクロロ−５−メトキシフェニル）アミノ］−６−アルコキシ−７−エチニル−３−キノリンカルボニトリル
WO2007005462A1 (en) *	2005-07-01	2007-01-11	Wyeth	Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
WO2012016082A1 (en) *	2010-07-30	2012-02-02	Oncotherapy Science, Inc.	Quinoline derivatives and melk inhibitors containing the same
CN103772392A (zh) *	2012-10-23	2014-05-07	杨子娇	一类治疗房角狭窄的化合物及其用途
TWI672141B (zh)	2014-02-20	2019-09-21	美商醫科泰生技	投予ｒｏｓ１突變癌細胞之分子
WO2015123758A1 (en) *	2014-02-20	2015-08-27	Apotex Inc.	Bosutinib forms and preparation methods thereof
US20160256457A1 (en) *	2014-06-10	2016-09-08	Beth Israel Deaconess Medical Center, Inc.	Methods for treating or preventing acute vascular leak
KR102595599B1 (ko)	2014-12-02	2023-11-02	이그니타, 인코포레이티드	신경모세포종의 치료를 위한 병용
WO2017029584A1 (en) *	2015-08-19	2017-02-23	Sun Pharmaceutical Industries Limited	Amorphous form of bosutinib
CN108697661A (zh)	2015-12-18	2018-10-23	亚尼塔公司	用于治疗癌症的组合
CN107814769B (zh) *	2016-09-14	2021-05-07	正大天晴药业集团股份有限公司	一种博舒替尼的纯化方法
EP3654952A1 (en)	2017-07-19	2020-05-27	Ignyta, Inc.	Pharmaceutical compositions comprising entrectinib
JP7311498B2 (ja)	2017-10-17	2023-07-19	イグナイタインコーポレイテッド	薬学的組成物および剤形
CN111646940B (zh) *	2019-03-04	2024-01-30	鲁南制药集团股份有限公司	一种博舒替尼中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6002008A (en) *	1997-04-03	1999-12-14	American Cyanamid Company	Substituted 3-cyano quinolines
US6297258B1 (en) *	1998-09-29	2001-10-02	American Cyanamid Company	Substituted 3-cyanoquinolines
US6521618B2 (en) *	2000-03-28	2003-02-18	Wyeth	3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) *	2002-04-30	2007-03-11	Wyeth Corp	Process for the preparation of 7-substituted-3- quinolinecarbonitriles
AU2003279795A1 (en) *	2002-10-04	2004-05-04	Caritas St.Elisabeth's Medical Center Of Boston, Inc.	Inhibition of src for treatment of reperfusion injury related to revascularization

2004
- 2004-02-18 TW TW093103901A patent/TW200423938A/zh unknown
- 2004-02-18 US US10/780,973 patent/US20040229880A1/en not_active Abandoned
- 2004-02-19 MX MXPA05008706A patent/MXPA05008706A/es unknown
- 2004-02-19 EP EP04712889A patent/EP1594502A1/en not_active Withdrawn
- 2004-02-19 AU AU2004216235A patent/AU2004216235A1/en not_active Withdrawn
- 2004-02-19 RU RU2005129333/04A patent/RU2005129333A/ru not_active Application Discontinuation
- 2004-02-19 WO PCT/US2004/004904 patent/WO2004075898A1/en not_active Ceased
- 2004-02-19 BR BR0407441-6A patent/BRPI0407441A/pt not_active IP Right Cessation
- 2004-02-19 JP JP2006503706A patent/JP2006522023A/ja not_active Withdrawn
- 2004-02-19 UA UAA200508924A patent/UA80472C2/uk unknown
- 2004-02-19 CA CA002516418A patent/CA2516418A1/en not_active Abandoned
- 2004-02-19 CN CNA2004800046743A patent/CN1750824A/zh active Pending
- 2004-02-19 KR KR1020057015377A patent/KR20050102133A/ko not_active Withdrawn
- 2004-02-20 AR ARP040100546A patent/AR043253A1/es not_active Application Discontinuation
2005
- 2005-08-03 CR CR7931A patent/CR7931A/es not_active Application Discontinuation
- 2005-08-17 CO CO05081472A patent/CO5640114A2/es not_active Application Discontinuation
- 2005-08-18 ZA ZA200506621A patent/ZA200506621B/en unknown
- 2005-08-19 EC EC2005005972A patent/ECSP055972A/es unknown
- 2005-09-01 NO NO20054070A patent/NO20054070L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20040229880A1 (en)	2004-11-18
WO2004075898A1 (en)	2004-09-10
MXPA05008706A (es)	2005-10-05
ZA200506621B (en)	2008-02-27
RU2005129333A (ru)	2006-01-27
TW200423938A (en)	2004-11-16
BRPI0407441A (pt)	2006-01-31
AU2004216235A1 (en)	2004-09-10
CR7931A (es)	2006-02-07
AR043253A1 (es)	2005-07-20
NO20054070L (no)	2005-11-14
EP1594502A1 (en)	2005-11-16
JP2006522023A (ja)	2006-09-28
KR20050102133A (ko)	2005-10-25
CA2516418A1 (en)	2004-09-10
ECSP055972A (es)	2006-01-16
NO20054070D0 (no)	2005-09-01
CN1750824A (zh)	2006-03-22
CO5640114A2 (es)	2006-05-31

Publication	Publication Date	Title
JP6775560B2 (ja)	2020-10-28	Ｊａｋ阻害剤としてのビピラゾール誘導体
WO2024067744A1 (zh)	2024-04-04	杂环取代喹唑啉及其制备方法和应用
JP4775259B2 (ja)	2011-09-21	アニリン誘導体
JP6665169B2 (ja)	2020-03-13	新規化合物αｖβ６インテグリンアンタゴニスト
AU2014337300B2 (en)	2019-01-03	Hydrochloride salt form for EZH2 inhibition
EP2820006B1 (en)	2017-08-02	Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists
AU2020261423B2 (en)	2026-01-29	Heterocyclic inhibitors of tyrosine kinase
JP2021514400A (ja)	2021-06-10	Ｅｇｆｒの阻害剤およびその使用法
KR20060041254A (ko)	2006-05-11	퀴놀론 유도체 또는 그의 염
SK61399A3 (en)	2000-02-14	HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa
JP6944442B2 (ja)	2021-10-06	疾患を治療するためのｍｃｔ４阻害剤
TW201505630A (zh)	2015-02-16	用於治療癌症之苯甲酸衍生物ｍｄｍ２抑制劑
KR20160029076A (ko)	2016-03-14	핵수송 조절인자 및 이의 용도
US20160214939A1 (en)	2016-07-28	Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CN111018891B (zh)	2021-12-03	作为长效dpp-iv抑制剂的取代的氨基六元饱和杂脂环类
KR20250012083A (ko)	2025-01-23	피페리딘일-메틸-푸린 아민 d-타르타르산 염, 결정질 형태 및 의학적 질환 및 병태 치료에서의 이들의 용도
KR20240158230A (ko)	2024-11-04	중수소-풍부 피페리디닐-메틸-퓨린 아민 및 관련 화합물 및 질환 및 병태 치료에 있어서 이것들의 용도
EP2951159A1 (en)	2015-12-09	Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
US20040229880A1 (en)	2004-11-18	4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
KR20260019517A (ko)	2026-02-10	3,4-디히드로프탈라진-1(2h)-온 유도체, 및 이의 제조 방법 및 이의 용도
KR20180085814A (ko)	2018-07-27	치환된 5,6-디히드로-6-페닐벤조[f]이소퀴놀린-2-아민의 제조 방법
HUE034721T2 (hu)	2018-02-28	Szubsztituált 2-alkil-1-oxo-N-fenil-3-heteroaril-1,2,3,4-tetrahidroizokinolin-4-karboxamidok maláriaellenes terápiákhoz
WO2022063333A1 (zh)	2022-03-31	一种嘧啶甲酰胺类化合物及其应用
CN112778273A (zh)	2021-05-11	环酮并吡啶酮类化合物及其制备方法和用途
TW202502765A (zh)	2025-01-16	一種prmt5抑制劑、其製備方法及應用